Across TCGA pan-cancer cohorts, OR6C76 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated OR6C76 data layer compared with 8 for mutation status.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher OR6C76 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR6C76 expression acts as an unfavorable survival marker.

BLCA, LIHC, and THCA are the cancer types where OR6C76 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Tertile	II,III,IV	0.320	0.622	<.001	144	view →
LIHC	DFS	Tertile	All	0.128	0.548	<.001	90	view →
THCA	DFS	Tertile	II,III,IV	0.671	0.922	<.001	72	view →
STAD	OS	Tertile	II,III,IV	0.434	0.723	.004	54	view →
MESO	DFS	Tertile	III,IV	0.082	0.414	.007	54	view →
KIRC	DFS	Tertile	IV	0.219	0.639	<.001	36	view →
GBM	DFS	Tertile	All	0.061	0.288	<.001	27	view →
LUAD	DFS	Tertile	IV	0.333	0.671	.048	18	view →
SARC	DFS	Tertile	All	0.095	0.632	.002	9	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

Exploration

Same gene, other analysis: OR6C76 tumor-vs-normal RNA expression · all OR6C76 data types